Land: New Zealand
Sprog: engelsk
Kilde: Medsafe (Medicines Safety Authority)
Dopamine hydrochloride 40 mg/mL;
Pfizer New Zealand Limited
Dopamine hydrochloride 40 mg/mL
200 mg/5mL
Solution for injection
Active: Dopamine hydrochloride 40 mg/mL Excipient: Sodium metabisulfite Water for injection
Ampoule, glass, Type I, clear, one point cut, 5 x 5mL, 25 mL
Prescription
Prescription
BASF PharmaChemikalien GmbH & Co KG
Latest Regulatory Activity
Package - Contents - Shelf Life: Ampoule, glass, Type I, clear, one point cut, 5 x 5mL - 25 mL - 36 months from date of manufacture stored at or below 30°C
1985-05-23
Version 5.0 Page 1 of 13 NEW ZEALAND DATA SHEET 1. PRODUCT NAME_ _ DBL ™ Sterile Dopamine Concentrate 2. QUALITATIVE AND QUANTITATIVE COMPOSITION DBL ™ Sterile Dopamine Concentrate is a sterile solution of Dopamine Hydrochloride BP in Water for Injection, containing 1% sodium metabisulfite. The strength supplied is 200 milligrams/5 mL in a clear glass ampoule. EXCIPIENT(S) WITH KNOWN EFFECT Sodium Metabisulfite For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM DBL ™ Sterile Dopamine Concentrate is a sterile solution for injection Dopamine hydrochloride is a white, odourless powder, freely soluble in water and soluble in alcohol. It is sensitive to light, alkalis, iron salts and oxidising agents. The pH of the solution is approximately 4. It must be diluted before use. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS For the correction of haemodynamic imbalance present in: Acute hypotension or shock associated with myocardial infarction, endotoxic septicaemia, trauma and renal failure. As an adjunct after open heart surgery, where there is persistent hypotension after correction of hypovolaemia. In chronic cardiac decompensation as in congestive failure. 4.2 DOSE AND METHOD OF ADMINISTRATION WARNING: DOPAMINE IS A POTENT DRUG. IT MUST BE DILUTED BEFORE ADMINISTRATION. DO NOT ADD TO ALKALINE SOLUTIONS SUCH AS SODIUM BICARBONATE, AS THESE INACTIVATE DOPAMINE. Version 5.0 Page 2 of 13 In appropriate cases, restoration of blood volume with plasma, whole blood, or a suitable plasma expander, should be instituted prior to administration: central venous pressure should be 10 to 15cm H 2 O, or pulmonary wedge pressure 14 to 18mm Hg. MODE OF ADMINISTRATION The rate of administration should be controlled in order to prevent inadvertent bolus administration: constant evaluation of therapy should be undertaken (ie. blood volume, ECG, arterial blood pressure, urine output, augmentation of myocardial contractility and distribution of peripheral perfusion. Measurement of central venous pressure an Læs hele dokumentet